ARGX-119 clinical trials
ARGX-119 is named as an intervention in 2 current clinical trials in our UK, USA, Canada, Australia, France, Spain and Italy registers. 1 is recruiting patients now. The most common phase is Phase 2. The lead sponsor is argenx. The most-studied condition is Spinal Muscular Atrophy (SMA).
How ARGX-119 works
All drug targets →- Amyotrophic lateral sclerosisPhase 2
- Spinal muscular atrophyPhase 2
- Congenital myasthenic syndromePhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL6068571, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for ARGX-119
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of ARGX-119
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
A Study to Assess the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Intravenous Administration of ARGX-119 in Pediatric Participants Aged 5 to Less Than 18 Years With Spinal Muscular Atrophy
NCT07287982 · Spinal Muscular Atrophy (SMA)
|
Phase 2 | Recruiting | argenx | UK, USA, Canada, Australia |
|
A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS)
NCT06436742 · Congenital Myasthenic Syndrome, CMS
|
Phase 1 | Active, closed | argenx | UK, USA, France, Spain, Italy, Canada |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with ARGX-119
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| argenx | 2 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in UK | 2 | 1 |
| Clinical trials in USA | 2 | 1 |
| Clinical trials in Canada | 2 | 1 |
| Clinical trials in Australia | 1 | 1 |
| Clinical trials in France | 1 | 0 |
| Clinical trials in Spain | 1 | 0 |
| Clinical trials in Italy | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about ARGX-119 trials
How many clinical trials are testing ARGX-119?
2 current trials in our UK, USA, Canada, Australia, France, Spain and Italy registers name ARGX-119 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are ARGX-119 trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in UK, 1 with sites in USA, 1 with sites in Canada and 1 with sites in Australia. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors ARGX-119 clinical trials?
The lead sponsor is argenx. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how ARGX-119 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how ARGX-119 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists ARGX-119 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.